Developer docs
API playgroundTry for free, no card

Search company profiles

Fortis Therapeutics

Full company profile

uuid00022b4

Namestring
Fortis Therapeutics
Legal namestring
Fortis Therapeutics, Inc.
Websiteurl
fortistx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Fortis Therapeutics is a privately held, clinical-stage immuno-oncology biotech founded in 2016 and headquartered in La Jolla, California (operating within COI Pharmaceuticals, Avalon's Community of Innovation in San Diego). The company is developing FOR46, a first-in-class antibody-drug conjugate (ADC) that targets CD46, a transmembrane complement inhibitory receptor that is highly expressed in tumor cells and forms part of the tumor's immune defense shield. FOR46 binds a tumor-specific conformational epitope of CD46, enabling targeted tumor cell killing while sparing normal tissues, with preclinical data demonstrating tumor elimination and long-term survival in rodent models of human prostate cancer.

The company's lead clinical programs target two late-stage oncology indications: metastatic castration-resistant prostate cancer (mCRPC), particularly in patients resistant to abiraterone or enzalutamide, and relapsed or refractory multiple myeloma, especially in patients with chromosome 1q21 amplification where CD46 expression is markedly elevated. The FDA cleared two IND applications for FOR46 in November 2018, and the company is currently conducting Phase 1 dose-escalation and expansion trials in both indications (NCT03575819 for mCRPC, NCT03650491 for multiple myeloma).

Fortis is pre-revenue and operates a traditional pharmaceutical go-to-market model, generating future revenue through drug commercialization upon regulatory approval (targeting oncologists, hematologists, and cancer treatment centers) or through potential out-licensing transactions. The company has raised $58 million across two Series A rounds ($18M in September 2016 led by Avalon Ventures, and $40M in March 2021 with existing investors plus new investors Myeloma Investment Fund and Fulcrum 2020, LLC). Its IP base is founded on technology exclusively licensed from UCSF (Bin Liu, Ph.D. laboratory), and its leadership team includes executives with track records of multiple FDA-approved oncology drug development programs at BioMarin, Lilly, Isis, Novartis, and the National Cancer Institute.

Short descriptiontext

Fortis Therapeutics is a clinical-stage immuno-oncology biotech developing FOR46, a first-in-class antibody-drug conjugate targeting CD46 for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, immuno-oncology therapeutics, CD46 targeted therapy, multiple myeloma treatment, prostate cancer therapeutics
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-Oncology Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company focused on developing FOR46 antibody-drug conjugate for treatment of late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

fortistx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fortis Therapeutics is developing FOR46, a first-in-class antibody-drug conjugate (ADC) that targets a tumor-specific conformational epitope of CD46, a complement inhibitory receptor highly expressed in tumor cells. The product is being advanced as a treatment for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC), with two Phase 1 clinical trials ongoing (NCT03650491 and NCT03575819). The ADC uses a fully human antibody conjugated to a potent cytotoxic payload via a proven linker-chemistry platform, designed to spare normal tissues while killing tumor cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 trial ongoing for mCRPC (NCT03575819) with dose escalation completed up to 3.0 mg/kg
+2 more records
Product overview1 text field

Fortis Therapeutics is developing a single lead product, FOR46, a novel antibody-drug conjugate (ADC) targeting CD46. The company is an immuno-oncology biotech focused on advancing this first-in-class therapeutic for the treatment of late-stage multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC). The ADC uses a fully human antibody conjugated to a potent payload using a proven chemistry platform, designed to direct precision therapies to CD46 proteins while sparing normal tissues.

Product and service1 record
1FOR46
CategoryAntibody-Drug Conjugate / Immuno-Oncology Therapeutic
Description

FOR46 is a first-in-class, fully human antibody-drug conjugate (ADC) targeting a tumor-specific conformational epitope of CD46, a complement inhibitory receptor highly expressed in tumor cells. It is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and relapsed/refractory multiple myeloma. The antibody is conjugated to a potent cytotoxic payload using a proven linker-chemistry platform, designed to spare normal tissues while killing CD46-expressing tumor cells. FOR46 is being evaluated in two Phase 1 clinical trials: NCT03575819 (mCRPC) and NCT03650491 (relapsed/refractory multiple myeloma).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

Fortis was founded based on technology exclusively licensed from UCSF, developed in the laboratory of Bin Liu, Ph.D. in the Department of Anesthesia. The company exclusively licensed rights to the FOR46 antibody in 2016 and maintains a strong intellectual property position.

Strategic tierCoreTypeOthers
Description

Fortis Therapeutics is located in COI Pharmaceuticals, Avalon's Community of Innovation, in San Diego. This provides shared infrastructure and operational support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical and commercial-stage ADC company developing targeted antibody-drug conjugates for hematologic and solid tumors. Closely comparable to Fortis as a focused ADC developer in oncology, though more advanced (multiple products in/approaching commercialization).

TypeDirect peer
Description

Clinical-stage biotech developing novel ADCs (e.g., XMT-1660, XMT-2056) for cancer. Directly comparable technology platform (ADC), similar development stage, and similar indication strategy in oncology.

TypeDirect peer
Description

Clinical-stage oncology biotech developing ADCs and immunotherapies against novel tumor antigens. Comparable as a small-cap ADC developer using differentiated antibody engineering against emerging targets.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing T-cell engager therapeutics. Closely tied to the Avalon Ventures / COI incubator that produced Fortis, sharing investors, infrastructure, and the same biotech-creation model in oncology.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing antibody-drug conjugates with immune-stimulating payloads (ISACs). Comparable as a clinical-stage ADC company with platform technology targeting solid tumors.

TypeEmerging player
Description

Clinical-stage company developing ADCs and other biologics using cell-free protein synthesis platform. Comparable technology category (ADCs) and similar clinical-stage oncology focus, though more advanced pipeline.

TypeBroad incumbent
Description

Pioneer in ADC technology and developer of Elahere (mirvetuximab) for ovarian cancer; acquired by AbbVie. Sets the bar as the established leader in the same ADC category Fortis operates in.

TypeBroad incumbent
Description

Market-leading ADC company (Adcetris, Padcev, Tukysa, Enhertu partnership with Daiichi Sankyo). The dominant commercial incumbent in the ADC space and a likely strategic acquirer or partner for clinical-stage ADC developers.

TypeEmerging player
Description

German clinical-stage biotech developing ADCs using the proprietary amanitin payload (different mechanism from Fort46's payload). Comparable clinical-stage ADC developer with a distinct payload/chemistry angle.

TypeEmerging player
Description

Clinical-stage biotech developing DARPin-based therapeutics for oncology, including immune-engaging candidates. Comparable as a clinical-stage, venture-backed oncology company with a differentiated targeting platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fortis Therapeutics

Immuno-Oncology Biopharmaceuticalsfortistx.com

Fortis Therapeutics is a clinical-stage immuno-oncology biotech developing FOR46, a first-in-class antibody-drug conjugate targeting CD46 for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer.

What Fortis Therapeutics does

Fortis Therapeutics is a privately held, clinical-stage immuno-oncology biotech founded in 2016 and headquartered in La Jolla, California (operating within COI Pharmaceuticals, Avalon's Community of Innovation in San Diego). The company is developing FOR46, a first-in-class antibody-drug conjugate (ADC) that targets CD46, a transmembrane complement inhibitory receptor that is highly expressed in tumor cells and forms part of the tumor's immune defense shield. FOR46 binds a tumor-specific conformational epitope of CD46, enabling targeted tumor cell killing while sparing normal tissues, with preclinical data demonstrating tumor elimination and long-term survival in rodent models of human prostate cancer.

The company's lead clinical programs target two late-stage oncology indications: metastatic castration-resistant prostate cancer (mCRPC), particularly in patients resistant to abiraterone or enzalutamide, and relapsed or refractory multiple myeloma, especially in patients with chromosome 1q21 amplification where CD46 expression is markedly elevated. The FDA cleared two IND applications for FOR46 in November 2018, and the company is currently conducting Phase 1 dose-escalation and expansion trials in both indications (NCT03575819 for mCRPC, NCT03650491 for multiple myeloma).

Fortis is pre-revenue and operates a traditional pharmaceutical go-to-market model, generating future revenue through drug commercialization upon regulatory approval (targeting oncologists, hematologists, and cancer treatment centers) or through potential out-licensing transactions. The company has raised $58 million across two Series A rounds ($18M in September 2016 led by Avalon Ventures, and $40M in March 2021 with existing investors plus new investors Myeloma Investment Fund and Fulcrum 2020, LLC). Its IP base is founded on technology exclusively licensed from UCSF (Bin Liu, Ph.D. laboratory), and its leadership team includes executives with track records of multiple FDA-approved oncology drug development programs at BioMarin, Lilly, Isis, Novartis, and the National Cancer Institute.

Fortis Therapeutics firmographics

Firmographics
Name
Fortis Therapeutics
Legal name
Fortis Therapeutics, Inc.
Website
https://fortistx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Fortis Therapeutics is a clinical-stage immuno-oncology biotech developing FOR46, a first-in-class antibody-drug conjugate targeting CD46 for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer.
Ownership category
akta.pro rank

Fortis Therapeutics industry classification

Industry
Product category
Immuno-Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody drug conjugates
  • Immuno-oncology therapeutics
  • CD46 targeted therapy
  • Multiple myeloma treatment
  • Prostate cancer therapeutics

Where Fortis Therapeutics is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Fortis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company focused on developing FOR46 antibody-drug conjugate for treatment of late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Marketing channels1 record

Fortis Therapeutics product offering

Product offering

Core offering

Fortis Therapeutics is developing FOR46, a first-in-class antibody-drug conjugate (ADC) that targets a tumor-specific conformational epitope of CD46, a complement inhibitory receptor highly expressed in tumor cells. The product is being advanced as a treatment for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC), with two Phase 1 clinical trials ongoing (NCT03650491 and NCT03575819). The ADC uses a fully human antibody conjugated to a potent cytotoxic payload via a proven linker-chemistry platform, designed to spare normal tissues while killing tumor cells.

Product overview

Fortis Therapeutics is developing a single lead product, FOR46, a novel antibody-drug conjugate (ADC) targeting CD46. The company is an immuno-oncology biotech focused on advancing this first-in-class therapeutic for the treatment of late-stage multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC). The ADC uses a fully human antibody conjugated to a potent payload using a proven chemistry platform, designed to direct precision therapies to CD46 proteins while sparing normal tissues.

Differentiator

Problem solved

Functional benefit

Products and services

  • FOR46 FOR46 is a first-in-class, fully human antibody-drug conjugate (ADC) targeting a tumor-specific conformational epitope of CD46, a complement inhibitory receptor highly expressed in tumor cells. It is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and relapsed/refractory multiple myeloma. The antibody is conjugated to a potent cytotoxic payload using a proven linker-chemistry platform, designed to spare normal tissues while killing CD46-expressing tumor cells. FOR46 is being evaluated in two Phase 1 clinical trials: NCT03575819 (mCRPC) and NCT03650491 (relapsed/refractory multiple myeloma).

Quantifiable outcome

  • Phase 1 trial ongoing for mCRPC (NCT03575819) with dose escalation completed up to 3.0 mg/kg
  • +2 more outcomes

Companies that use Fortis Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Fortis Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Fortis Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • UCSF (University of California, San Francisco)coreTechnology or Integration · 1 January 2016Fortis was founded based on technology exclusively licensed from UCSF, developed in the laboratory of Bin Liu, Ph.D. in the Department of Anesthesia. The company exclusively licensed rights to the FOR46 antibody in 2016 and maintains a strong intellectual property position.
  • COI PharmaceuticalscoreOthersFortis Therapeutics is located in COI Pharmaceuticals, Avalon's Community of Innovation, in San Diego. This provides shared infrastructure and operational support.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Fortis Therapeutics competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Clinical and commercial-stage ADC company developing targeted antibody-drug conjugates for hematologic and solid tumors. Closely comparable to Fortis as a focused ADC developer in oncology, though more advanced (multiple products in/approaching commercialization).
  • Mersana Therapeutics: Clinical-stage biotech developing novel ADCs (e.g., XMT-1660, XMT-2056) for cancer. Directly comparable technology platform (ADC), similar development stage, and similar indication strategy in oncology.
  • Pyxis Oncology: Clinical-stage oncology biotech developing ADCs and immunotherapies against novel tumor antigens. Comparable as a small-cap ADC developer using differentiated antibody engineering against emerging targets.
  • Janux Therapeutics: Clinical-stage immuno-oncology company developing T-cell engager therapeutics. Closely tied to the Avalon Ventures / COI incubator that produced Fortis, sharing investors, infrastructure, and the same biotech-creation model in oncology.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing antibody-drug conjugates with immune-stimulating payloads (ISACs). Comparable as a clinical-stage ADC company with platform technology targeting solid tumors.

Emerging players

  • Sutro Biopharma: Clinical-stage company developing ADCs and other biologics using cell-free protein synthesis platform. Comparable technology category (ADCs) and similar clinical-stage oncology focus, though more advanced pipeline.
  • Heidelberg Pharma: German clinical-stage biotech developing ADCs using the proprietary amanitin payload (different mechanism from Fort46's payload). Comparable clinical-stage ADC developer with a distinct payload/chemistry angle.
  • Molecular Partners: Clinical-stage biotech developing DARPin-based therapeutics for oncology, including immune-engaging candidates. Comparable as a clinical-stage, venture-backed oncology company with a differentiated targeting platform.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC technology and developer of Elahere (mirvetuximab) for ovarian cancer; acquired by AbbVie. Sets the bar as the established leader in the same ADC category Fortis operates in.
  • Seagen (Pfizer): Market-leading ADC company (Adcetris, Padcev, Tukysa, Enhertu partnership with Daiichi Sankyo). The dominant commercial incumbent in the ADC space and a likely strategic acquirer or partner for clinical-stage ADC developers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Fortis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fortis Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Fortis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fortis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fortis Therapeutics

What does Fortis Therapeutics do?

Fortis Therapeutics is developing FOR46, a first-in-class antibody-drug conjugate (ADC) that targets a tumor-specific conformational epitope of CD46, a complement inhibitory receptor highly expressed in tumor cells. The product is being advanced as a treatment for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC), with two Phase 1 clinical trials ongoing (NCT03650491 and NCT03575819). The ADC uses a fully human antibody conjugated to a potent cytotoxic payload via a proven linker-chemistry platform, designed to spare normal tissues while killing tumor cells.

Is Fortis Therapeutics a public or private company?

Fortis Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fortis Therapeutics founded?

Fortis Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Fortis Therapeutics based?

Fortis Therapeutics is headquartered in La Jolla, United States, in the North America region.

How does Fortis Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Fortis Therapeutics's main competitors?

Direct peers on record are ADC Therapeutics, Mersana Therapeutics, Pyxis Oncology, Janux Therapeutics and Bolt Biotherapeutics. Emerging players are Sutro Biopharma, Heidelberg Pharma and Molecular Partners. Broad incumbents are ImmunoGen (AbbVie) and Seagen (Pfizer).

Does Fortis Therapeutics have an API?

No public API is recorded for Fortis Therapeutics.

What industry is Fortis Therapeutics in?

Fortis Therapeutics's product category is Immuno-Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaFibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In TheFibroGen Inc announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (FOR46), an anti-CD46 antibody drug conjugate for metastatic castration-resistant prostate cancer, showing 36% PSA reductions over 50% and 20% partial response rate with median duration of 7.5 months. The median radiographic progression-free survival was 8.7 months in this heavily pretreated patient population. William Blair analysts view the results as numerically improved efficacy relative to alternate novel hormone therapies and are advocating for additional exploration, with FibroGen planning to consult with the FDA and commence Phase 2 studies in the latter half of the year.GlobeNewswireFibroGen Enters into Exclusive License for FOR46 with Fortis TherapeuticsFibroGen entered an exclusive license with Fortis Therapeutics for FOR46, a CD46-targeting antibody-drug conjugate in Phase 1 for mCRPC. The deal has no upfront consideration, with FibroGen funding development and an option to acquire Fortis for $80 million plus up to $200 million in regulatory milestones.socaltech.comFortis Therapeutics Gets $40M For Cancer TreatmentsFortis Therapeutics, a San Diego biotech startup developing treatments for late-stage prostate cancer and multiple myeloma, raised $40M in Series A financing. The funding came from Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, Vivo Capital, and new investors.VC News DailyFortis Therapeutics Closes $40M Series AFortis Therapeutics, an immuno-oncology biotech based in San Diego, announced the close of a $40 million Series A financing round. The funding was co-led by existing investors Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital, alongside new investors Myeloma Investment Fund, Multiple Myeloma Research Foundation, and Prostate Cancer Foundation. The capital will support development of the company's novel antibody-drug conjugate targeting late-stage multiple myeloma and metastatic castration-resistant prostate cancer, with technology exclusively licensed from UCSF.PR NewswireFortis Therapeutics Closes $18 Million Series A Financing to Advance New Antibody Drug Conjugate Therapies for the Treatment of Late-Stage CancersFortis Therapeutics, a San Diego-based immuno-oncology biotech, announced the close of an $18 million Series A financing led by Avalon Ventures with participation from Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital. The company is developing antibody drug conjugate therapies targeting a receptor over-expressed in late-stage prostate cancer and multiple myeloma, based on technology exclusively licensed from UC San Francisco. Eric J. Small, a prominent UCSF oncologist and deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, was appointed to head the company's scientific advisory board.